PubMed=2004854; DOI=10.1002/ijc.2910470518
Kuroda H., Sugimoto T., Ueda K., Tsuchida S., Horii Y., Inazawa J., Sato K., Sawada T.
Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy.
Int. J. Cancer 47:732-737(1991)

DOI=10.1007/0-306-46872-7_2
Thiele C.J.
Neuroblastoma.
(In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999)

PubMed=12702577
Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A., Sugimoto T., Inazawa J.
PPM1D is a potential target for 17q gain in neuroblastoma.
Cancer Res. 63:1876-1883(2003)

PubMed=23268333; DOI=10.1016/j.canlet.2012.12.011
Sugimoto T., Gotoh T., Yagyu S., Kuroda H., Iehara T., Hosoi H., Ohta S., Ohira M., Nakagawara A.
A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Cancer Lett. 331:115-121(2013)

CLPUB00582
Sugimoto T., Kuroda H., Yagyu S., Gotoh T., Osone S., Tamura S., Iehara T., Hosoi H.
Cellular and molecular characteristics of established neuroblastoma cell lines.
J. Cancer Res. Therap. Oncol. 7:201.1-201.15(2019)